Cover Image
市場調查報告書

腹膜腫瘤:開發中產品分析

Peritoneal Tumor - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 208485
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
腹膜腫瘤:開發中產品分析 Peritoneal Tumor - Pipeline Review, H1 2014
出版日期: 2014年03月31日 內容資訊: 英文 69 Pages
簡介

腹膜癌是罕見的癌症,是被覆於腹部的一層薄膜組織上發生的癌症。也會蔓延到子宮、膀胱、直腸。常見的症狀有腹部不適(脹氣、消化不良、壓力、腫脹、膨脹感、痙攣等)及腹痛、(輕食後的)膨脹感、嘔吐或下痢、便秘、頻尿和食慾不振等。主要的治療方法包含化療和放射線治療等。

本報告提供腹膜腫瘤的治療藥開發情形調查分析,提供您開發中的產品概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

腹膜腫瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Eli Lilly and Company
  • Cell Therapeutics, Inc.
  • MEI Pharma, Inc.
  • Recepta Biopharma S.A.
  • AbbVie Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • trebananib
  • paclitaxel poliglumex
  • idronoxil
  • ramucirumab
  • RebmAb-100
  • nintedanib
  • Carcinoembryonic Antigen-Expressing Measles Virus Vaccine
  • ABT-767
  • Pb-TCMC-Trastuzumab

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4763IDB

Global Markets Direct's, 'Peritoneal Tumor - Pipeline Review, H1 2014', provides an overview of the Peritoneal Tumor's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peritoneal Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Tumor and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peritoneal Tumor
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Peritoneal Tumor and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Peritoneal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Peritoneal Tumor pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Peritoneal Tumor
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Peritoneal Tumor pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peritoneal Tumor Overview
  • Therapeutics Development
    • Pipeline Products for Peritoneal Tumor - Overview
    • Pipeline Products for Peritoneal Tumor - Comparative Analysis
  • Peritoneal Tumor - Therapeutics under Development by Companies
  • Peritoneal Tumor - Therapeutics under Investigation by Universities/Institutes
  • Peritoneal Tumor - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Peritoneal Tumor - Products under Development by Companies
  • Peritoneal Tumor - Products under Investigation by Universities/Institutes
  • Peritoneal Tumor - Companies Involved in Therapeutics Development
    • Boehringer Ingelheim GmbH
    • Amgen Inc.
    • Eli Lilly and Company
    • Cell Therapeutics, Inc.
    • MEI Pharma, Inc.
    • Recepta Biopharma S.A.
    • AbbVie Inc.
  • Peritoneal Tumor - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • trebananib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paclitaxel poliglumex - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • idronoxil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ramucirumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RebmAb-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nintedanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ABT-767 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ²¹²Pb-TCMC-Trastuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Peritoneal Tumor - Recent Pipeline Updates
  • Peritoneal Tumor - Dormant Projects
  • Peritoneal Tumor - Discontinued Products
  • Peritoneal Tumor - Product Development Milestones
    • Featured News & Press Releases
      • Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer
      • Oct 22, 2010: M's Science Corporation Sells Its HF10 Oncology Business To Takara Bio Inc.
      • Sep 17, 2010: M's Science Corporation Initiates Exclusive Negotiations With Takara Bio Inc. To Sell Its HF10 Oncology Business
      • Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group
      • Oct 16, 2009: National Patent Granted For Developmental Product HF 10
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peritoneal Tumor, H1 2014
  • Number of Products under Development for Peritoneal Tumor - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Peritoneal Tumor - Pipeline by Boehringer Ingelheim GmbH, H1 2014
  • Peritoneal Tumor - Pipeline by Amgen Inc., H1 2014
  • Peritoneal Tumor - Pipeline by Eli Lilly and Company, H1 2014
  • Peritoneal Tumor - Pipeline by Cell Therapeutics, Inc., H1 2014
  • Peritoneal Tumor - Pipeline by MEI Pharma, Inc., H1 2014
  • Peritoneal Tumor - Pipeline by Recepta Biopharma S.A., H1 2014
  • Peritoneal Tumor - Pipeline by AbbVie Inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Peritoneal Tumor Therapeutics - Recent Pipeline Updates, H1 2014
  • Peritoneal Tumor - Dormant Projects, H1 2014
  • Peritoneal Tumor - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Peritoneal Tumor, H1 2014
  • Number of Products under Development for Peritoneal Tumor - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top